Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI355 in Moderate-to-Severe Sjögren's Disease
NCT07836660Phase 2Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Oct 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IBI-355 in Sjögren's syndrome (4 arms), sponsored by Innovent Biologics. Primary endpoint: EULAR Sjögren's Syndrome Disease Activity Index at 24 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
IBI-355
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT07836660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836660.